Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

about

Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Item

http://www.wikidata.org/entity/Q49713310

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Prognostic Impact of Missed Ch ...... or Non-Small Cell Lung Cancer.

@en

Prognostic Impact of Missed Ch ...... or Non-Small Cell Lung Cancer.

@nl

type

Item

label

Prognostic Impact of Missed Ch ...... or Non-Small Cell Lung Cancer.

@en

Prognostic Impact of Missed Ch ...... or Non-Small Cell Lung Cancer.

@nl

prefLabel

Prognostic Impact of Missed Ch ...... or Non-Small Cell Lung Cancer.

@en

Prognostic Impact of Missed Ch ...... or Non-Small Cell Lung Cancer.

@nl

P1476

Prognostic Impact of Missed Ch ...... or Non-Small Cell Lung Cancer.

@en

P2093

Bruno S Fang

http://www.w3.org/2001/XMLSchema#string

Inaya Ahmed

http://www.w3.org/2001/XMLSchema#string

Joseph Aisner

http://www.w3.org/2001/XMLSchema#string

Jyoti Malhotra

http://www.w3.org/2001/XMLSchema#string

Matthew P Deek

http://www.w3.org/2001/XMLSchema#string

Salma K Jabbour

http://www.w3.org/2001/XMLSchema#string

Sinae Kim

http://www.w3.org/2001/XMLSchema#string

Wei Zou

http://www.w3.org/2001/XMLSchema#string

P2860

Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.

Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.

Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two facto

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.

Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation.

Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.

Clinically relevant determinants of body composition, function and nutritional status as mortality predictors in lung cancer patients.

The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study.

P31

scholarly article

P356

10.1097/COC.0000000000000293

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27322697

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

5767542

http://www.w3.org/2001/XMLSchema#string